Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "HARBOR Trial - Elenestinib, an Investigational, Next Gen KIT D816V Inhibitor, in Patients With Indolent Systemic Mastocytosis"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Tsewang Tashi
By
Insights from 2023 ASH Annual Meeting
FEATURING
Tsewang Tashi
Login to view comments.
Click here to Login